Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1‑related anti‑apoptotic proteins

Saranaruk,Paksiree; Kariya,Ryusho; Sittithumcharee,Gunya; Boueroy,Parichart; Boonmars,Thidarut; Sawanyawisuth,Kanlayanee; Wongkham,Chaisiri; Wongkham,Sopit; Okada,Seiji; Vaeteewoottacharn,Kulthida

doi:10.3892/ijmm.2020.4482

Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1‑related anti‑apoptotic proteins

Authors:
- Paksiree Saranaruk
- Ryusho Kariya
- Gunya Sittithumcharee
- Parichart Boueroy
- Thidarut Boonmars
- Kanlayanee Sawanyawisuth
- Chaisiri Wongkham
- Sopit Wongkham
- Seiji Okada
- Kulthida Vaeteewoottacharn
View Affiliations

Affiliations: Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand, Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection and Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860‑0811, Japan, Faculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon 47000, Japan, Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand
Published online on: January 29, 2020 https://doi.org/10.3892/ijmm.2020.4482
Pages: 1005-1016
Copyright: © Saranaruk et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a cancer of biliary epithelium. Late diagnosis and resistance to conventional chemotherapy are the major obstacles in CCA treatment. Increased expression of anti‑apoptotic proteins are observed in CCA, which might confer chemoresistance. Thus, modulations of anti‑apoptotic proteins leading to apoptotic induction is the focus of this study. Chromomycin A3 (CMA3), an anthraquinone glycoside‑mithramycin A analog, was selected. CMA3 strongly binds to GC‑rich regions in DNA, where specificity protein 1 (Sp1), a common transcription factor of apoptosis‑related proteins, is preferentially bounded. The effects of CMA3 on anti‑proliferation, cell cycle arrest and apoptosis induction in CCA cells were demonstrated by MTT assay, flow cytometry and western blot analysis. The results showed CMA3 suppressed cell proliferation in vitro in the nM range. At low doses, CMA3 inhibited cell cycle progression at S phase, while it promoted caspase‑dependent apoptosis at higher doses. CMA3 induced effects of apoptosis were through the suppression of Sp1‑related anti‑apoptotic proteins, FADD‑like IL‑1β‑converting enzyme‑inhibitory protein, myeloid cell leukemia‑1, X‑linked inhibitor of apoptosis protein, cellular inhibitor of apoptosis and survivin. The anti‑CCA effects of CMA3 were confirmed in the xenograft mouse model. CMA3 retarded xenograft tumor growth. Taken together, CMA3 induced apoptosis in CCA cells by diminishing the Sp1‑related anti‑apoptotic proteins is demonstrated. CMA3 might be useful as a chemosensitizing agent.

View Figures

View References

1	Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, et al: Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 13:261–280. 2016. View Article : Google Scholar : PubMed/NCBI
2	Sripa B, Bethony JM, Sithithaworn P, Kaewkes S, Mairiang E, Loukas A, Mulvenna J, Laha T, Hotez PJ, Brindley PJ, et al: Opisthorchiasis and opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop. 120(Suppl 1): S158–S168. 2011. View Article : Google Scholar
3	Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P and Thomas HC: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
4	Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
5	Marin JJ, Romero MR and Briz O: Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem. 17:709–740. 2010. View Article : Google Scholar : PubMed/NCBI
6	Dhanasekaran R, Hemming AW, Zendejas I, George T, Nelson DR, Soldevila-Pico C, Firpi RJ, Morelli G, Clark V and Cabrera R: Treatment outcomes and prognostic factors of intra-hepatic cholangiocarcinoma. Oncol Rep. 29:1259–1267. 2013. View Article : Google Scholar : PubMed/NCBI
7	Srimunta U, Sawanyawisuth K, Kraiklang R, Pairojkul C, Puapairoj A, Titipungul T, Hahnvajanawong C, Tassaneeyakul W, Wongkham C, Wongkham S and Vaeteewoottacharn K: High expression of ABCC1 indicates poor prognosis in intrahepatic chol-angiocarcinoma. Asian Pac J Cancer Prev. 13(Suppl): S125–S130. 2012.
8	Prakobwong S, Gupta SC, Kim JH, Sung B, Pinlaor P, Hiraku Y, Wongkham S, Sripa B, Pinlaor S and Aggarwal BB: Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis. 32:1372–1380. 2011. View Article : Google Scholar : PubMed/NCBI
9	Pawar P, Ma L, Byon CH, Liu H, Ahn EY, Jhala N, Arnoletti JP, McDonald JM and Chen Y: Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: Role of calmodulin. Clin Cancer Res. 15:1288–1296. 2009. View Article : Google Scholar : PubMed/NCBI
10	Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH and Gores GJ: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64:3517–3524. 2004. View Article : Google Scholar : PubMed/NCBI
11	Yamagiwa Y, Marienfeld C, Meng F, Holcik M and Patel T: Translational regulation of X-linked inhibitor of apoptosis protein by interleukin-6: A novel mechanism of tumor cell survival. Cancer Res. 64:1293–1298. 2004. View Article : Google Scholar : PubMed/NCBI
12	Chang Q, Liu ZR, Wang DY, Kumar M, Chen YB and Qin RY: Survivin expression induced by doxorubicin in cholangiocar-cinoma. World J Gastroenterol. 10:415–418. 2004. View Article : Google Scholar : PubMed/NCBI
13	Beishline K and Azizkhan-Clifford J: Sp1 and the 'hallmarks of cancer'. FEBS J. 282:224–258. 2015. View Article : Google Scholar
14	Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J and Xie K: Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 9:6371–6380. 2003.PubMed/NCBI
15	Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA and Lu D: Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 17:1648–1652. 2008. View Article : Google Scholar : PubMed/NCBI
16	Vizcaino C, Mansilla S and Portugal J: Sp1 transcription factor: A long-standing target in cancer chemotherapy. Pharmacol Ther. 152:111–124. 2015. View Article : Google Scholar : PubMed/NCBI
17	Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS and Kwon TK: Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther. 5:2737–2746. 2006. View Article : Google Scholar : PubMed/NCBI
18	Choi ES, Nam JS, Jung JY, Cho NP and Cho SD: Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 4:71622014. View Article : Google Scholar : PubMed/NCBI
19	Barcelo F, Ortiz-Lombardia M, Martorell M, Oliver M, Méndez C, Salas JA and Portugal J: DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry. 49:10543–10552. 2010. View Article : Google Scholar : PubMed/NCBI
20	Chatterjee S, Zaman K, Ryu H, Conforto A and Ratan RR: Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol. 49:345–354. 2001. View Article : Google Scholar : PubMed/NCBI
21	Gause GF: Olivomycin, mithramycin, chromomycin: Three related cancerostatic antibiotics. Adv Chemother. 2:179–195. 1965. View Article : Google Scholar : PubMed/NCBI
22	Schmitz H, Heinemann B, Lein J and Hooper IR: NSC A-649, an antitumor antibiotic. Antibiot Chemother (Northfield). 10:740–746. 1960.
23	Reynolds RD, Fisher JI, Jensen PA, Pajak TF and Bateman JR: Phase I alternate-day dose study of chromomycin A3. Cancer Treat Rep. 60:1251–1255. 1976.PubMed/NCBI
24	Samal B, Jones S, Brownlee RW, Morrison F, Hoogstraten B, Caoili E and Baker L: Chromomycin A3 for advanced breast cancer: A Southwest oncology group study. Cancer Treat Rep. 62:19–22. 1978.PubMed/NCBI
25	Iranpour FG, Nasr-Esfahani MH, Valojerdi MR and al-Taraihi TM: Chromomycin A3 staining as a useful tool for evaluation of male fertility. J Assist Reprod Genet. 17:60–66. 2000. View Article : Google Scholar : PubMed/NCBI
26	Boer DR, Canals A and Coll M: DNA-binding drugs caught in action: The latest 3D pictures of drug-DNA complexes. Dalton Trans. 399–414. 2009. View Article : Google Scholar : PubMed/NCBI
27	Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP and Xia M: Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol. 79:1272–1280. 2010. View Article : Google Scholar : PubMed/NCBI
28	Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C and Miwa M: Establishment and characterization of an opisthorchiasis-associated cholan-giocarcinoma cell line (KKU-100). World J Gastroenterol. 11:3392–3397. 2005. View Article : Google Scholar : PubMed/NCBI
29	Saisomboon S, Kariya R, Vaeteewoottacharn K, Wongkham S, Sawanyawisuth K and Okada S: Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocar-cinoma in vitro and in an in vivo xenograft model. Heliyon. 5:e016752019. View Article : Google Scholar
30	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
31	Phoomak C, Silsirivanit A, Park D, Sawanyawisuth K, Vaeteewoottacharn K, Wongkham C, Lam EW, Pairojkul C, Lebrilla CB and Wongkham S: O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. Oncogene. 37:5648–5665. 2018. View Article : Google Scholar : PubMed/NCBI
32	Cerella C, Muller F, Gaigneaux A, Radogna F, Viry E, Chateauvieux S, Dicato M and Diederich M: Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. Cell Death Dis. 6:e17822015. View Article : Google Scholar : PubMed/NCBI
33	Cai J, Wang D, Bai ZG, Yin J, Zhang J and Zhang ZT: The long noncoding RNA XIAP-AS1 promotes XIAP transcription by XIAP-AS1 interacting with Sp1 in gastric cancer cells. PLoS One. 12:e01824332017. View Article : Google Scholar : PubMed/NCBI
34	Obchoei S, Weakley SM, Wongkham S, Wongkham C, Sawanyawisuth K, Yao Q and Chen C: Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer. 10:1022011. View Article : Google Scholar : PubMed/NCBI
35	Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H, Suzu S and Okada S: Comparative study of human hematopoietic cell engraftment into BALB/c and C57BL/6 strain of rag-2/jak3 double-deficient mice. J Biomed Biotechnol. 2011:5397482011. View Article : Google Scholar : PubMed/NCBI
36	Harlow E and Lane D: Preparing paraffin tissue sections for immunostaining. CSH Protoc. 2006:pdb.prot43292006.PubMed/NCBI
37	Vaeteewoottacharn K, Kariya R, Dana P, Fujikawa S, Matsuda K, Ohkuma K, Kudo E, Kraiklang R, Wongkham C, Wongkham S and Okada S: Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma. Tumour Biol. 37:9023–9035. 2016. View Article : Google Scholar : PubMed/NCBI
38	Parrish AB, Freel CD and Kornbluth S: Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol. 5:a0086722013. View Article : Google Scholar : PubMed/NCBI
39	Bedolla RG, Gong J, Prihoda TJ, Yeh IT, Thompson IM, Ghosh R and Kumar AP: Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. PLoS One. 7:e449172012. View Article : Google Scholar : PubMed/NCBI
40	Lau R, Niu MY and Pratt MA: cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation. Cell Cycle. 11:4009–4019. 2012. View Article : Google Scholar : PubMed/NCBI
41	Patel T: Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol. 8:189–200. 2011. View Article : Google Scholar : PubMed/NCBI
42	Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH and Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 128:2054–2065. 2005. View Article : Google Scholar : PubMed/NCBI
43	Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS and Enger PO: Drug repurposing in cancer. Pharmacol Res. 124:74–91. 2017. View Article : Google Scholar : PubMed/NCBI
44	Guimaraes LA, Jimenez PC, Sousa Tda S, Freitas HP, Rocha DD, Wilke DV, Martín J, Reyes F, Deusdênia Loiola Pessoa O and Costa-Lotufo LV: Chromomycin A2 induces autophagy in melanoma cells. Mar Drugs. 12:5839–5855. 2014. View Article : Google Scholar : PubMed/NCBI